MX2009007295A - Uso de antigeno de fusion d de proteina a3 mage en inmunoterapia combinado con cirugia, quimioterapia o radioterapia para el tratamiento de cancer. - Google Patents

Uso de antigeno de fusion d de proteina a3 mage en inmunoterapia combinado con cirugia, quimioterapia o radioterapia para el tratamiento de cancer.

Info

Publication number
MX2009007295A
MX2009007295A MX2009007295A MX2009007295A MX2009007295A MX 2009007295 A MX2009007295 A MX 2009007295A MX 2009007295 A MX2009007295 A MX 2009007295A MX 2009007295 A MX2009007295 A MX 2009007295A MX 2009007295 A MX2009007295 A MX 2009007295A
Authority
MX
Mexico
Prior art keywords
radiotherapy
chemotherapy
surgery
cancer
treatment
Prior art date
Application number
MX2009007295A
Other languages
English (en)
Inventor
Catherine Marie Ghislaine Gerard
Vincent Brichard
Jamila Louahed
Frederic Francois Eugene Lehmann
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2009007295A publication Critical patent/MX2009007295A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una terapia de combinación que comprende una inmunoterapia basada en un antígeno de tumor o un derivado inmunológico del mismo, y por lo menos otro tratamiento para cáncer tal como quimioterapia, radioterapia y/o cirugía.
MX2009007295A 2007-01-08 2008-01-08 Uso de antigeno de fusion d de proteina a3 mage en inmunoterapia combinado con cirugia, quimioterapia o radioterapia para el tratamiento de cancer. MX2009007295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700284.3A GB0700284D0 (en) 2007-01-08 2007-01-08 Combination therapy
PCT/EP2008/050133 WO2008084040A1 (en) 2007-01-08 2008-01-08 Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2009007295A true MX2009007295A (es) 2009-07-14

Family

ID=37801846

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007295A MX2009007295A (es) 2007-01-08 2008-01-08 Uso de antigeno de fusion d de proteina a3 mage en inmunoterapia combinado con cirugia, quimioterapia o radioterapia para el tratamiento de cancer.

Country Status (12)

Country Link
US (1) US20100008980A1 (es)
EP (1) EP2099470A1 (es)
JP (1) JP2010515670A (es)
KR (1) KR20090099011A (es)
CN (1) CN101578105A (es)
AU (1) AU2008204526A1 (es)
BR (1) BRPI0806257A2 (es)
CA (1) CA2674315A1 (es)
EA (1) EA200900735A1 (es)
GB (1) GB0700284D0 (es)
MX (1) MX2009007295A (es)
WO (1) WO2008084040A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012623A (es) * 2009-05-27 2011-12-14 Glaxosmithkline Biolog Sa Construcciones de casb7439.
US20130031794A1 (en) 2011-08-05 2013-02-07 Duff Jr Ronald Richard RAZOR BLADES WITH ALUMINUM MAGNESIUM BORIDE (AlMgB14)-BASED COATINGS
RU2014122867A (ru) * 2011-12-22 2016-02-20 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK
AU2018366131A1 (en) * 2017-11-08 2020-05-28 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
US7771998B2 (en) * 2001-11-29 2010-08-10 Dandrit Biotech A/S Pharmaceutical composition for inducing an immune response in a human or animal
CA2653402A1 (en) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals S.A. Method

Also Published As

Publication number Publication date
EA200900735A1 (ru) 2010-02-26
GB0700284D0 (en) 2007-02-14
KR20090099011A (ko) 2009-09-18
JP2010515670A (ja) 2010-05-13
AU2008204526A1 (en) 2008-07-17
WO2008084040A8 (en) 2008-08-28
BRPI0806257A2 (pt) 2011-08-30
US20100008980A1 (en) 2010-01-14
EP2099470A1 (en) 2009-09-16
CA2674315A1 (en) 2008-07-17
CN101578105A (zh) 2009-11-11
WO2008084040A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
MX2024015039A (es) Composiciones anti-cd24 y usos de las mismas
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
IL184617A0 (en) Dr5 antibodies and uses thereof
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2010003520A3 (en) Anti-tumor immunotherapy
EP4233909A3 (en) Anti-cmet antibody drug conjugates and methods for their use
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2007115045A3 (en) Diagnostics and treatments for tumors
MX2011010955A (es) Terapia complementaria contra el cancer.
CA3055791A1 (en) Treatment methods
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
NZ737471A (en) Hydrophilic linkers for conjugation
NZ603271A (en) Anti-erbb3 antibodies
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2007061874A3 (en) Methods and compositions for use in treating cancer
EP3895725A3 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
MY146112A (en) Long-term feed - cancer patient
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
WO2010054377A3 (en) Fully human antibodies against n-cadherin

Legal Events

Date Code Title Description
FA Abandonment or withdrawal